Tag Archive for: Clinical Trial

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

/in

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation   Turin, Italy […]

Read more

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

/in

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission to EMA for conversion to full marketing authorization planned for Q4 2026 Lund, Sweden, May 27, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: […]

Read more

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

/in

Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001 Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more […]

Read more

STORM Therapeutics to present promising Phase 1 sarcoma data demonstrating activity of first‑in‑class METTL3 inhibitor STC‑15 at ASCO 2026

/in

Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression 22 May 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announces that a subset analysis of sarcoma patients enrolled […]

Read more

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

/in

 — STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) and high endothelial venule (HEV) formation in the tumor as well as clinical responses, as monotherapy and in combination with […]

Read more
© Optimum Strategic Communications.